Skip to main content

Advertisement

SpringerLink
Log in

Gene expression-based diagnosis of efficacy of chemotherapy for breast cancer

  • Special Feature
  • Breast cancer research from bench to bedside
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Development of a clear index to select drugs, i.e., accurate prediction of drug sensitivity, is important not only to obtain the maximum therapeutic effects of drugs, but also realize personalized medicine (tailor-made medicine). With the recent advancement in genome science represented by microarrays, molecular-level elucidation of many diseases including cancers has been progressing. It has been clarified that molecular information, such as gene expression profiles of cancer cells and gene polymorphisms in individual patients, affects not only cancer development and progression, but also therapeutic and adverse effects. The establishment of a therapeutic method by clinical application of this information has been progressing, in which the therapeutic effects of drugs are accurately predicted, and the maximum effects are obtained corresponding to cancer properties and patients’ characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. In: 10th St. Gallen conference. Ann Oncol. 2007;18:1133–44.

  2. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362–9.

    Article  CAS  PubMed  Google Scholar 

  3. Iwao-Koizumi K, Matoba R, Ueno N, Kim SJ, Ando A, Miyoshi Y, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol. 2005;23:422–31.

    Article  CAS  PubMed  Google Scholar 

  4. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004;22:2284–93.

    Article  CAS  PubMed  Google Scholar 

  5. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006;24:4236–44.

    Article  CAS  PubMed  Google Scholar 

  6. Kihara C, Tsunoda T, Tanaka T, Yamana H, Furukawa Y, Ono K, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 2001;61:6474–9.

    CAS  PubMed  Google Scholar 

  7. Kakiuchi S, Daigo Y, Ishikawa N, Furukawa C, Tsunoda T, Yano S, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004;13:3029–43.

    Article  CAS  PubMed  Google Scholar 

  8. Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, et al. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2009;113:275–83.

    Article  CAS  PubMed  Google Scholar 

  9. Zembutsu H, Suzuki Y, Sasaki A, Tsunoda T, Okazaki M, Yoshimoto M, et al. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol. 2009;34:361–70.

    CAS  PubMed  Google Scholar 

  10. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–7.

    Article  PubMed  Google Scholar 

  11. Foekens JA, Atkins D, Zhang Y, Sweep FC, Harbeck N, Paradiso A, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol. 2006;24:1665–71.

    Article  CAS  PubMed  Google Scholar 

  12. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531–7.

    Article  CAS  PubMed  Google Scholar 

  13. Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA. 1999;96:9212–7.

    Article  CAS  PubMed  Google Scholar 

  14. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.

    Article  PubMed  Google Scholar 

  15. Massagué J. Sorting out breast-cancer gene signatures. N Engl J Med. 2007;356:294–7.

    Article  PubMed  Google Scholar 

  16. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.

    Article  CAS  PubMed  Google Scholar 

  17. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726–34.

    Article  CAS  PubMed  Google Scholar 

  18. van‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530–6.

    Article  Google Scholar 

  19. van de Vijver MJ, He YD, Van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999–2009.

    Article  PubMed  Google Scholar 

  20. Wu RZ, Bailey SN, Sabatini DM. Cell-biological applications of transfected-cell microarrays. Trends Cell Biol. 2002;12:485–8.

    Article  CAS  PubMed  Google Scholar 

  21. Vanhecke D, Janitz M. High-throughput gene silencing using cell arrays. Oncogene. 2004;23:8353–8.

    Article  CAS  PubMed  Google Scholar 

  22. Fujita S, Ota E, Sasaki C, Takano K, Miyake M, Miyake J. Highly efficient reverse transfection with siRNA in multiple wells of microtiter plates. J Biosci Bioeng. 2007;104:329–33.

    Article  CAS  PubMed  Google Scholar 

  23. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature. 2007;446:815–9.

    Article  CAS  PubMed  Google Scholar 

  24. Nagasaki K, Miki Y. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer. Breast Cancer. 2008;15:117–20.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan

    Yoshio Miki

Authors
  1. Yoshio Miki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshio Miki.

About this article

Cite this article

Miki, Y. Gene expression-based diagnosis of efficacy of chemotherapy for breast cancer. Breast Cancer 17, 97–102 (2010). https://doi.org/10.1007/s12282-009-0180-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-009-0180-2

Keywords

Search

Navigation